Research ArticleOMERACT

Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11

Laura C. Coates, Oliver FitzGerald, Philip J. Mease, Dafna D. Gladman, Vibeke Strand, Niti Goel, Ina Campbell, Gerald Krueger, Neil J. McHugh and Philip S. Helliwell
The Journal of Rheumatology April 2014, 41 (4) 782-791; DOI: https://doi.org/10.3899/jrheum.131250

REFERENCES

  1. 1.↵
    1. Gladman DD,
    2. Mease PJ,
    3. Krueger G,
    4. van der Heidje DM,
    5. Antoni C,
    6. Helliwell PS,
    7. et al.
    Outcome measures in psoriatic arthritis. J Rheumatol 2005;32:2262–9.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Gladman DD,
    2. Mease PJ,
    3. Strand V,
    4. Healy P,
    5. Helliwell PS,
    6. Fitzgerald O,
    7. et al.
    Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167–70.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Isenberg DA,
    2. Rahman A,
    3. Allen E,
    4. Farewell V,
    5. Akil M,
    6. Bruce IN,
    7. et al.
    BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902–6.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Gladman DD,
    2. Landewe R,
    3. McHugh NJ,
    4. Fitzgerald O,
    5. Thaci D,
    6. Coates L,
    7. et al.
    Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010;37:453–61.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Feldman SR,
    2. Krueger GG
    . Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65–8; discussion ii9–73.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Gladman DD,
    2. Helliwell P,
    3. Mease PJ,
    4. Nash P,
    5. Ritchlin C,
    6. Taylor W
    . Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24–35.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mease PJ
    . Assessment tools in psoriatic arthritis. J Rheumatol 2008;35:1426–30.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Mease PJ,
    2. Antoni CE,
    3. Gladman DD,
    4. Taylor WJ
    . Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii49–54.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Mease PJ,
    2. Menter MA
    . Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685–704.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. van der Heijde D,
    2. Sharp J,
    3. Wassenberg S,
    4. Gladman DD
    . Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005;64 Suppl 2:ii61–4.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Fransen J,
    2. Antoni C,
    3. Mease PJ,
    4. Uter W,
    5. Kavanaugh A,
    6. Kalden JR,
    7. et al.
    Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373–8.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Coates LC,
    2. FitzGerald O,
    3. Gladman DD,
    4. McHugh NJ,
    5. Mease P,
    6. Strand V,
    7. et al.
    Reduced joint counts misclassify psoriatic arthritis patients with oligoarthritis and miss significant active disease. Arthritis Rheum 2013;65:1504–9.
    OpenUrlPubMed
  13. 13.↵
    1. Clegg DO,
    2. Reda DJ,
    3. Mejias E,
    4. Cannon GW,
    5. Weisman MH,
    6. Taylor T,
    7. et al.
    Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013–20.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Gladman DD,
    2. Tom BD,
    3. Mease PJ,
    4. Farewell VT
    . Informing response criteria for psoriatic arthritis. I: Discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol 2010;37:1892–7.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Nell-Duxneuner VP,
    2. Stamm TA,
    3. Machold KP,
    4. Pflugbeil S,
    5. Aletaha D,
    6. Smolen JS
    . Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546–9.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Eberl G,
    2. Studnicka-Benke A,
    3. Hitzelhammer H,
    4. Gschnait F,
    5. Smolen JS
    . Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology 2000;39:148–55.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Fredriksson T,
    2. Pettersson U
    . Severe psoriasis—oral therapy with a new retinoid. Dermatologica 1978;157:238–44.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Langley RG,
    2. Ellis CN
    . Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004; 51:563–9.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Berth-Jones J,
    2. Thompson J,
    3. Papp K
    . A study examining interrater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008;159:407–12.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Jones SM,
    2. Armas JB,
    3. Cohen MG,
    4. Lovell CR,
    5. Evison G,
    6. McHugh NJ
    . Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994;33:834–9.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Cassell SE,
    2. Bieber JD,
    3. Rich P,
    4. Tutuncu ZN,
    5. Lee SJ,
    6. Kalunian KC,
    7. et al.
    The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34:123–9.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Healy PJ,
    2. Helliwell PS
    . Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 2007;34:1302–6.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Helliwell PS,
    2. Firth J,
    3. Ibrahim GH,
    4. Melsom RD,
    5. Shah I,
    6. Turner DE
    . Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745–50.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Gladman DD,
    2. Inman RD,
    3. Cook RJ,
    4. van der Heijde D,
    5. Landewe RB,
    6. Braun J,
    7. et al.
    International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007;34:1733–9.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Eder L,
    2. Chandran V,
    3. Shen H,
    4. Cook RJ,
    5. Gladman DD
    . Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010;69:2160–4.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Fernandez-Sueiro JL,
    2. Willisch A,
    3. Pertega-Diaz S,
    4. Tasende JA,
    5. Fernandez-Lopez JC,
    6. Villar NO,
    7. et al.
    Validity of the Bath Ankylosing Spondylitis Disease Activity Index for the evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res 2010;62:78–85.
    OpenUrlCrossRef
  27. 27.↵
    1. Taylor WJ,
    2. Harrison AA
    . Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51:311–5.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Ritchlin CT,
    2. Kavanaugh A,
    3. Gladman DD,
    4. Mease PJ,
    5. Helliwell P,
    6. Boehncke WH,
    7. et al.
    Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Mumtaz A,
    2. Gallagher P,
    3. Kirby B,
    4. Waxman R,
    5. Coates LC,
    6. Veale JD,
    7. et al.
    Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272–7.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Sterry W,
    2. Ortonne JP,
    3. Kirkham B,
    4. Brocq O,
    5. Robertson D,
    6. Pedersen RD,
    7. et al.
    Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Fitzgerald O,
    2. Helliwell P,
    3. Mease P,
    4. Mumtaz A,
    5. Coates L,
    6. Pedersen R,
    7. et al.
    Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis 2012;71:358–62.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Cauli A,
    2. Gladman D,
    3. Mathieu A,
    4. Olivieri I,
    5. Ujfalussy I,
    6. Scarpa R,
    7. et al.
    Patient and physician perception of disease in psoriatic arthritis (PsA). A Multicentre GRAPPA and OMERACT study [abstract]. Arthritis Rheum 2007;56 Suppl:S264.
    OpenUrl
  33. 33.↵
    1. Helliwell PS,
    2. Fitzgerald O,
    3. Fransen J,
    4. Gladman DD,
    5. Kreuger GG,
    6. Callis-Duffin K,
    7. et al.
    The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986–91.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Fransen J,
    2. Kavanaugh A,
    3. Borm G
    . Desirability scores for assessing multiple outcomes in systemic rheumatic diseases. Commun Stat Theory Methods 2009;38:3461–71.
    OpenUrlCrossRef
  35. 35.↵
    1. Coates LC,
    2. Fransen J,
    3. Helliwell PS
    . Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48–53.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section

Keywords

PSORIATIC ARTHRITIS
CLINICAL OUTCOME MEASURES
ASSESSMENT
DISEASE ACTIVITY

Keywords